CORRESPONDENCE

Comment on Lachenmeier *et al* (2020) “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”: disputation on various points in the publication [version 1; peer review: 2 approved]

Daniel Kruse , Bernhard Beitzke

European Industrial Hemp Association (EIHA), Hürth, NRW, 50354, Germany

V1 First published: 04 Aug 2020, 9:900
<https://doi.org/10.12688/f1000research.25354.1>
Latest published: 04 Aug 2020, 9:900
<https://doi.org/10.12688/f1000research.25354.1>

Abstract

This Correspondence article is a counterstatement to a Brief Report published by Lachenmeier and co-workers on 17th February 2020 in F1000Research: “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”. This counterstatement proposes that the authors of that article neither present proof or evidence for the alleged side effects of CBD products (no case reports presented with utilisable data), nor do they show that side effects are due to the presence of THC.

Primarily, there is no clear definition of THC because the authors do not explain whether they mean Delta9-THC only (without its precursor tetrahydrocannabinolic acid (THCA)) or total-THC (the sum of Delta9-THC and its precursor THCA, normalised to THC); indeed EU Recommendation 2016/2115 on the monitoring of cannabinoids in food requires the measurement and documentation of the precursor acids complementary to the decarboxylated cannabinoids. The key part of the authors’ work – Table 2 with the assessment of the CBD products – leaves the reader in the dark about the nature of “THC”. This is all the more concerning because acid-free Delta9-THC is psychotropic but THCA is not.

Additionally, the classification of the CBD products (“toxicity assessment”) presented is based on the assignment of the quantitative relation to the LOAEL (lowest observed adverse effect level) of THC (2.5 mg of acid-free Delta9-THC per adult and day as assigned by EFSA, 2015). However, many assumptions by Lachenmeier *et al.* on daily intake of CBD products are questionable, in particular food supplements, where the recommended daily consumption was missing on the label.

Finally, the authors of the paper also compare their findings with the German recommendations on maximum levels of total-THC in food, ignoring that those limits refer to total-THC and the ready-to-eat

Open Peer Review

Approval Status

	1	2
version 1
04 Aug 2020	view	view
1. Gerhard Nahler , CIS Clinical Investigation Support GmbH, Vienna, Austria		
2. Gianpaolo Grassi , Council for Agricultural Research and Economics (CREA-CIN), Rovigo, Italy		
Any reports and responses or comments on the article can be found at the end of the article.		

products, and not to the food ingredient itself – in particular hemp tea products.

Keywords

Cannabidiol, tetrahydrocannabinol, hemp, illegality, daily intake, toxicity, side effects

Corresponding author: Bernhard Beitzke (consultancy@beitzke.de)

Author roles: **Kruse D:** Conceptualization, Formal Analysis, Project Administration, Resources, Supervision, Visualization, Writing – Review & Editing; **Beitzke B:** Data Curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Writing – Original Draft Preparation

Competing interests: DK is the President of the European Industrial Hemp Association (EIHA); BB is member of the EIHA Advisory Committee. The EIHA is the European association of the hemp processing industry with about 250 members in more than 30 countries. The EIHA, based in Brussels (Belgium), represents the interests of industrial hemp producers and traders on a pan-European and national level. The industrial hemp sector includes the cultivation and processing of hemp fibres and seeds as well as cannabinoids. The EIHA therefore represents the common interests of hemp farmers, producers and traders working with hemp fibres, shives, seeds, leaves and cannabinoids. EIHA's main task is to serve, protect and represent the hemp sector in the EU and international policy-making. EIHA covers different areas for the application of hemp, namely its use for construction materials, textiles, cosmetics, feed, food and supplements. EIHA confirms that funding was not granted to this specific piece of research, but was part of the general work of the association's tasks as stated above.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Kruse D and Beitzke B. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kruse D and Beitzke B. **Comment on Lachenmeier *et al* (2020) "Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?": disputation on various points in the publication [version 1; peer review: 2 approved]** F1000Research 2020, 9:900 <https://doi.org/10.12688/f1000research.25354.1>

First published: 04 Aug 2020, 9:900 <https://doi.org/10.12688/f1000research.25354.1>

Introduction

This Correspondence article was written by members of the European Industrial Hemp Association (EIHA; <https://eiha.org/>) and EIHA Advisory Committee to highlight their concerns about the Brief Report published by Lachenmeier *et al.*¹ on 17th February 2020 in F1000Research: “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”. The content and argumentation of the Brief Report has alienated our organization in many ways. For this reason, as a European professional association, we feel compelled to comment on this publication and its content.

The article by Lachenmeier *et al.* revealed the following:

- purported THC-like side effects aimed to show of CBD or CBD-containing products cannot be sequelae of CBD conversion to THC by gastric fluid but are the effects of the residual THC in such products;
- CBD-containing hemp products (teas, extracts sold as food supplements) give rise to THC-like side effects because in many cases either the LOAEL or the European Acute Reference Dose of THC will be exceeded after consumption of such products;
- the high THC-content of CBD products is a “scandal on the food market”, and food business operators “placed unsafe and approved products on the market”;
- the current regulatory framework were “insufficient to adequately regulate products in the grey area between medicines and food supplements”.

Alleged side effects of CBD products

Firstly, it should be noted that, as the authors themselves admit, cases of alleged side effects of products containing CBD claimed in the publication are anecdotal. It is striking that no reference is given as proof of evidence. Instead, the authors try to present findings on effects of Epidiolex® as evidence for their statement on CBD-containing hemp products. Indeed, the reference to rare side effects of the Epidiolex® studies is displaced, especially since Epidiolex® (against special forms of children's epilepsy) is “pure” CBD with a much higher dosing regimen for a pharmaceutical/metabolic action and cannot be compared with low dosed CBD oils and hemp extracts with naturally present levels of Cannabinoids. On the contrary, it has been suggested that some adverse effects of CBD in the clinical studies (for Epidiolex®) may relate to interactions with other antiepileptic drugs². Moreover, an assessment of the drug status of Epidiolex® by the US Public Health Service came to the conclusion: “Thus, it is unlikely that THC contributed to the slight positive responses on some of the subjective measures or

*contributed to the euphoric [adverse event] responses reported following the higher doses of CBD.”*³

Hence the question is: have the purported side effects after uptake of CBD oils or hemp extracts been measured and proven? Have there been serious side effects showing that these products were not safe, and which products exactly gave rise to the reported side-effects?

All this is not explained in the article by Lachenmeier *et al.*, although the title of this publication suggests that these side effects are hard facts. No reference or proof is given for the alleged side effects of the CBD products in question. Furthermore, a statement by the British FSA (FSA 20-01-03)⁴ states:

“18. We have not been made aware of any safety incidents relating to CBD products on the market, so we are not planning to insist on an immediate removal of the products from the shelves. That said, it is important that industry puts these products through the authorisation process as the process is there ...”

This statement is representative for CBD products all over Europe because the UK was and is an important market for the Food Business Operators (FBOs) on the European continent.

“THC” definition and estimation of daily dose of products

The main subject of the article by Lachenmeier *et al.* is “THC”, which is neither precisely defined in the publication nor correctly explained, i.e. there is no differentiation between Delta9-THC (acid-free) and Delta9-tetrahydrocannabinolic acid (THCA), the latter being the non-psychotropic precursor of THC and not contributing to the “toxic effects” of “THC”⁵. From the raw data published in Table 2 of Lachenmeier *et al.*, the type of THC cannot be defined for each case, i.e. whether this should mean total-THC (which is the sum of Delta9-THCA, corrected by the molecular weight factor, and Delta9-THC) or Delta9-THC (acid-free) only.

Pursuant to the EU Recommendation 2016/2115⁶ on the monitoring of cannabinoids in food, THC should be differentiated correctly between Delta9-THC and its precursor THCA; their respective concentrations should be measured separately,

¹ “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?” by Lachenmeier *et al.* in the online Journal F1000Research 2020, 8:1394; Last updated 17 Feb 2020

² Geoffrey *et al.*: Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy, *Epilepsia* 56(8): 1246–51, 2015

³ U.S. Public Health Service, Dep. of Health and Human Services, Office of the Secretary, Letter to the DEA, dated May 16, 2018; Enclosure: Basis for the recommendation to place Cannabidiol in Schedule V of the Controlled Substances Act., Chapter B.2, page 12 (Residual THC Levels)

⁴ FSA (2020). ‘Food Standards Agency Board meeting – 21 January 2020’. FSA, 3 January. <https://www.food.gov.uk/sites/default/files/media/document/fsa-20-01-03-chief-executives-report-final.pdf>

⁵ Dewey, W.L. 1986. Cannabinoid pharmacology. *Pharmacol Rev* 38(2):151–178;

G. Moreno-Sanz: Can You Pass the Acid Test ? Critical Review and Novel Therapeutic Perspectives of Δ⁹-Tetrahydrocannabinolic Acid A, *Cannabis Cannabinoid Res.* 1.1 (2016).

⁶ <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016H2115>

and the contents of both compounds documented correctly, in particular in a scientific paper.

In favour of the authors, we will assume here that the “THC” measured and mentioned in the publication refers only to Delta9-THC (acid-free), and that the analytical method used for this purpose is able to quantify the latter separately from THCA (*note*: natural products that have not been heated always contain a part as THCA)⁷. This is also relevant for the samples containing cannabidiolic acid (CBDA) and/or cannabigerolic acid (CBGA) (5 samples tested), as most probably the main part of their “THC”-content consists of THCA, which should not be included in the toxicity assessment based on the Delta9-THC content.

Moreover, the statement in Lachenmeier *et al.* “*Out of 67 samples, 17 samples (25% of the collective) were exceeding the THC LOAEL [Lowest Observed Adverse Effect Level] and were assessed as harmful to human health...*” is not scientifically correct and cannot be assumed as hard fact. The “THC” level is in fact the result of the measurement of the “THC” concentration by analysis, while the LOAEL is the lowest amount of a substance, which, when measuring certain effects in animal or human studies, shows just observable adverse effect(s). The missing link between the result from the analysis and the dictum of “*LOAEL has been exceeded*” is the (recommended) daily dose of the specific product together with its measured THC-concentration. These data are only available in the raw data published by Lachenmeier *et al.*⁸ which should be shown in the publication itself. It should also be noted that for those products for which a recommended daily dose was missing on the label, the authors made an estimation of these daily doses. In many cases, however, they assumed a very high daily dose, which in our view is far from being practical, as can be illustrated by the following examples:

Tea products (hemp flowers or leaves): the authors base their calculation on a “*probable intake of 2 portions/day*” (8 g of tea leaves or flowers per person daily), or they assume a daily consumption for tea products taking into account a worst case scenario, concluding the “*LOAEL may be exceeded*”. However, in Table 2 it is stated that the THC-LOAEL **is** exceeded (marked in red). This is confusing to readers who will be unable to distinguish which statement is correct.

Furthermore, the THC intake for all tea products is calculated by multiplication of the estimated daily portion with the measured THC-content in the hemp tea leaves, hence the

authors insinuate the ingestion of 100% of the THC found in the hemp “tea leaves”. This type of calculation is not correct. Firstly, a 100% carry-over of THC into the tea preparation (infusion) has been refuted in the scientific literature⁹. Secondly, as to the German guidelines on total-THC-content in foodstuff, the THC guidance value for tea beverages refers to the ready-to-eat or ready-to-drink products and not to the hemp “tea leaves” green matter. Among EIHA members, there are FBO’s who have been testing hemp leaf infusions in water for years, and these reports are available¹⁰. This type of estimation may lead FBOs to wonder why they recommend a daily dose on the label as well as a brewing instruction, if this is then ignored or overruled by an authority in the evaluation of marketability.

Syrup with hemp flower extract: a daily portion of 130 g is assumed (because of a missing recommended dose), thus exceeding European Food Safety Authority (EFSA)’s Acute Reference Dose (ARfD)¹¹. One third of this amount (43 g/d) would usually be an extremely high daily intake of syrup for human consumption in everyday practice and would result in a THC intake below the ARfD (approx. 56 µg/d). This would not be admonished, for example in Austria¹². The assignment of a daily dose of 130 g therefore seems to have been arbitrary and possibly results-oriented only.

Cannabis shot: a daily dose of 60 g is estimated and assumed, which even for a food supplement is objectively to be regarded as very exceptional and extremely high; this amount results in a THC uptake of only 8 µg/d. This product is admonished by Lachenmeier *et al.* for exceeding the German guidance for THC-levels in food, even though they are actually not regulated by law let alone made binding. In addition, the German recommendations apply to total-THC (including THC acids) and only for ready-to-eat products (i.e. those which the consumer finally ingests after preparation).

CBD oil: first line in Table 2, the following assumption was made (see footnote 2) about this product: “*No labelling about dosage provided on the label. For this reason the consumption of the whole bottle at once as worst case exposure scenario was assumed.*”. In all objectivity, this is exaggerated and not a realistic scenario. First, we can assume that it is well known to the consumer of a food supplement on how to take it.

⁷ If it were total-THC, it would not allow any conclusions on the possible daily intake and thus on reaching or not reaching the LOAEL because the latter has been derived by EFSA on the basis of studies with Delta9-THC [Acid-free] only. Consequently, the Acute Reference Dose (ARfD) derived by EFSA in its scientific opinion only refers to Delta9-THC [acid-free].

⁸ Lachenmeier, D. W. (2020, April 26). Dataset for “Are side effects of cannabidiol (CBD) products caused by delta9-tetrahydrocannabinol (THC) contamination?” <https://doi.org/10.17605/OSF.IO/F7ZXY>

⁹ Hazekamp *et al.*, Cannabis tea revisited: A systematic evaluation of the cannabinoid composition of cannabis tea, *J. Ethnopharmacol.* 113 (2007) 85–90

¹⁰ Test reports are available on request from EIHA.

¹¹ EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2015. Scientific Opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. *EFSA Journal* 2015;13(6):4141, 125 pp. doi:10.2903/j.efsa.2015.4141

¹² Austria has no recommendations or limit values for maximum levels of THC in foodstuffs. There authorities only determine the conformity with the ARfD for Delta9-THC [acid-free] from the EFSA recommendation.

Therefore, the consumer will not take the contents of the entire container or bottle at once. The typical consumer of a food supplement is most likely a well-informed person proactively following a healthy lifestyle, feeling responsible for their own health, and who is therefore willing to purchase products that will help to maintain and to strengthen homeostasis – to stay healthy for a longer lifespan. Second, a food supplement is not a basic food (see legal definition of “food supplements” in Art. 2 lit. a of Regulation 2002/46/EC¹³). Third, if there are food supplements with “CBD oil” on the market without correct labelling (e.g. without a recommended daily intake) this constitutes the wrongdoing of some individual market players and not of the whole industry.

For some samples with the recommended daily dose missing on the product label (marked with footnote 4, Table 2, in Lachenmeier *et al.*), the basis for the toxicity assessment is unclear from Table 2, whereas in the raw data there is a daily portion given (e.g. 5.0 g for the “CBD buds” or 8.0 g for “Hemp tea with flowers”) and this portion is used for the daily THC-intake calculation.

Considering these examples, the data in Table 2, on which the publication is based, are derived from unclear premises on the nature of “THC” and the daily dosing of the CBD-containing products. Many parts are arbitrarily based on assumptions that are out of touch with reality, and which we do not consider justified.

Admittedly, a dosage or recommended daily intake should always be found on the label of food supplements (see Article 8(2) of Regulation 2002/46/EC). The recommended intake that consumers usually find on the packaging of the products should be clear and concise, and it should be explicitly indicated “not to exceed the recommended dose” and “food supplements should not be used as a substitute for a healthy and varied diet”. However, the many cases in which the respective manufacturers have done this correctly seem to be dismissed by the authors.

Assessment of the impact of CBD products

The assumption stated in the publication by Lachenmeier *et al.* that “the adverse effects of commercial CBD-products” (still to be proven by evidence) “are based on a low dose effect of THC and not due to effects of CBD itself” lacks sufficient scientific and comprehensible justification as this is only based on the known toxicological effects of isolated Delta9-THC (precisely synthetic Delta9-THC). The interaction between Delta9-THC and CBD, which has been investigated in many studies, is not taken into account here by the authors. Obviously, however, the scientific community is aware that the effects of “THC” are indeed mitigated by CBD (see e.g. Zuardi *et al.*, 1982¹⁴). A more recent publication on “Lower-Risk

Cannabis”¹⁵ even recommends with the note: “Given the evidence of CBD’s attenuating effects on some THC-related outcomes, it is advisable to use cannabis containing high CBD:THC ratios. Evidence Grade: Substantial.”. The mechanisms of this interaction are not fully elucidated yet, however, currently it is acknowledged that CBD is a negative allosteric modulator of the CB1 receptor¹⁶. It is surprising that the authors do not mention these well-known scientific findings.

Alleged “illegality” of all hemp products containing CBD

The authors further claim: “Basically all available CBD products based on hemp extract marketed as food or food supplement within the EU are therefore illegally sold”. Although this is a regulatory issue, we think it is necessary to comment on this blanket statement.

A general statement on the non-conformity of all available CBD-products with EU regulations is, in our opinion, outside of the scope of the publication. As stated already many times by jurisdiction, the assessment, for example on compliance with the Novel Food Regulation (EU), is always a case-to-case evaluation by authorities or at court. It must also be emphasized that the European Novel Food Catalogue is legally not binding (see legal disclaimer on the corresponding website of the EU COM¹⁷). For court decisions, the entries in the NF Catalogue are just indicators or circumstantial/presumptive evidence. Moreover, the burden of proof for the novelty of a food is up to the person or body who makes this statement, whereas the economic operator(s) bear(s) a so-called secondary burden of proof, if necessary, which, however, must not lead to the reversal of the burden of proof¹⁸. Although the Federal Administrative Court in Germany (BVerwG) has not yet had to make an explicit statement on this legal issue, in a decision on 29 January 2010 it already indicated that it has doubts about the burden of proof regulation, which some administrative courts have practised elsewhere to date¹⁹.

Since experience shows that the federal courts in Germany coordinate their case-law on one and the same provision among themselves, it can be assumed that the BVerwG will

¹³ <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32002L0046>

¹⁴ Zuardi *et al.*: Action of Cannabidiol on the Anxiety and Other Effects Produced by Δ⁹-THC in Normal Subjects, *Psychopharmacol.* 1982(76): 245-50.

¹⁵ Fischer *et al.*: Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations, *Am J Public Health.* 2017 August; 107(8): e1–e12, Published online 2017 August. doi: [10.2105/AJPH.2017.303818](https://doi.org/10.2105/AJPH.2017.303818).

¹⁶ Pisanti *et al.*: Cannabidiol: State of the Art and new challenges for therapeutic applications, *Pharmacol. Ther.*, 2017 (175), 133–50.

¹⁷ https://ec.europa.eu/info/legal-notice_en

¹⁸ BGH GRUR 2015, 1140; <https://dejure.org/dienste/vernetzung/rechtsprechung?Gericht=BGH&Datum=16.04.2015&Aktenzeichen=I%20ZR%2027/14>

Hegele, *Zeitschrift für das gesamte Lebensmittelrecht (ZLR)*, Germany, 2012, 317, 322 f.

¹⁹ BVerwG decision of 29 January 2010, 3 B 84/09

<https://dejure.org/dienste/vernetzung/rechtsprechung?Gericht=BVerwG&Datum=29.01.2010&Aktenzeichen=3%20B%2084.09>

ultimately follow the aforementioned legal interpretation of the Federal Court of Justice. This is also in view of the fact that the European Court of Justice (ECJ) already imposes the burden of proof on the party claiming the existence of a pharmacological effect of a foodstuff in cases of doubt. The BVerwG has already fully endorsed this legal interpretation of the ECJ on the rule on the burden of proof there²⁰.

Hence, the ECJ did not impose the burden of proof of the non-existence of a pharmacological effect of a foodstuff on the FBO concerned. Therefore, it is all the more unlikely that the ECJ now should come to a different rule on the burden of proof in the issue of a possible “novelty” within the meaning of the Novel Food Regulation and an associated abstract health risk, according to which the FBO were required to prove the non-existence of a “novelty”. This would be completely contrary to the legal doctrine as well as to the factual system.

What an authority can do, of course, is to conclude within its expertise on the non-marketability of a specific product because it is “unsafe” for the consumer within the meaning of Article 14(1) and (2) of Regulation (EC) No 178/2002²¹, i.e. injurious to health or unfit for human consumption (and this is the primary realm of the local authority). However, such decisions must also be based on scientific evidence (cf. Article 3 et seq. of Regulation (EC) No 178/2002).

Value judgement on food producers of hemp products

Lachenmeier *et al.* also claim that “*In our opinion the systematically high THC content of CBD products is clearly a “scandal” on the food market. Obviously, the manufacturers have – deliberately or in complete ignorance of the legal situation – placed unsafe and unapproved products on the market and thus exposed the consumer to an actually avoidable risk.*”

We consider this sweeping and polemical value judgement misplaced in a scientific work. Reputable, professional producers of food and food supplements always ensure the quality and safety of their products in all steps of production and also observe legal compliance with European and national regulations. These producers have a well-established quality assurance and control for their products and ensure correct labelling, in particular for correct consumer information with a recommendation on the daily intake of the product.

In fact, the legal situation is not as clear as purported by the authors, and it cannot be generally stated that all CBD-containing products are Novel Foods under the European Novel Food Regulation. At the end of 1997, even the EU Commission with its Standing 2015/2283 Committee on Foodstuffs had established

and confirmed that foods that contain parts of the hemp plant, such as hemp flowers, are not covered by Regulation (EC) No. 258/97 on Novel Foods and Novel Food ingredients²².

In Germany, the Federal Government publicly declared the following in the German Bundestag: “*The opinions of the European Commission confirming that foods containing parts of the hemp plant are not novel foods remain valid. However, it cannot be concluded from them that all products of the hemp plant, including isolated individual substances such as cannabinoids or extracts enriched with cannabinoids, would be marketable as food. In addition ... it must always be checked whether a product in its composition was used as a foodstuff to any significant extent in the EU before 15 May 1997. Otherwise, as in the case of cannabinoids, it must be considered as a novel food*”²³.

The EIHA has already presented evidence to the European Commission, according to which hemp extracts have been consumed as food for centuries, and that the so-called “low-THC” varieties from *Cannabis sativa* L. (thus “industrial hemp” or “usefulness hemp”) have always contained CBD. At this point, it should be mentioned that especially in these industrial hemp varieties – including those that were listed in the EU catalogue of varieties long before 1997 – the relevant CBD content in relation to THC is very high in comparison to “high-THC” cannabis varieties. Therefore, such hemp extracts (e.g. those not enriched with CBD) are traditional food and will not fall under the Novel Food Regulation.

Hence, the statement by Lachenmeier *et al.* that the products are unsafe is another blanket statement and must refer to products only that have been in fact proven unsafe for consumption according to current requirements. However, this publication does not scientifically verify this and presents no proof. Moreover, it has been decided many times by jurisdiction that the decision on the novelty of a food is always based on a case-to-case evaluation of the special product in question.

Admittedly, there are always so-called “cowboys” or “black sheep” in the market – as in every industry – disregarding the regulations, trying to make a quick profit with the hype around “legalisation of cannabis” and cannabinoids. This phenomenon is unfortunately also evident in cases of questionable quality and insufficient attention to labelling (e.g. missing recommended intake).

However, discrimination can also occur from undifferentiated action of the authorities with regard to quality and the legal

²⁰ BVerwG, judgment of 26 May 2009 - 3 C 5.09

<https://dejure.org/dienste/vernetzung/rechtsprechung?Gericht=BVerwG&Datum=26.05.2009&Aktenzeichen=3%20C%205.09>

²¹ <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32002R0178>

²² Letters from the EU Commission to SonnenHaus ÖKO-Handels GmbH of February 3, 1998, and to Alfredo Dupetit Natural Products of March 3, 1998; <https://eiha.org/media/2019/05/EIHA-PRESS-NOTES-EXTRACTS.pdf> (see page 4). Copies of the letter are provided on request.

Presentation by M. Reinders: Bringing hemp based products to market, 4th Dec 2019, Cannabis Innovation Hub, London, see charts 16, 17.

²³ Statement of the Federal Government in the German Bundestag of 25.07.2019, printed matter 19/11922, p.2.

<http://dipbt.bundestag.de/extrakt/ba/WP19/2506/250681.html>

situation vis-à-vis respectable market participants, which clearly leads to abstruse marketing strategies of so called “free riders”. Such companies, for example sell plain hemp seed oil through pharmacies at exorbitant prices and suggest to the consumer that it is a particularly effective drug or food supplement²⁴. This situation is also EIHA’s concern because this jeopardises the reputation of the hemp industry. However, EIHA, as an association of voluntary members of farmers and producers, can only exert positive influence on its own members, but cannot discipline other unwilling market participants. Therefore, EIHA cannot itself control the market, but could help the authorities to regulate it in a scientifically sound, safe and reasonable way – subject to constructive dialogs and cooperation. EIHA therefore demands clear industry standards that are mandatory for all FBO’s in the sector to ensure compliance with the law, consumer safety and also legal certainty for businesses. Work is underway to harmonise the “self-regulated” quality standards of some national interest groups or individual economic operators. The time spent by EIHA and its members as companies in defending themselves against the arbitrariness of individual authorities could be used more efficiently and constructively in mutual dialogue. Unfortunately, earlier offers of exchange and cooperation in Germany, unlike in other European countries, have so far been largely ignored. This should also be mentioned against the background that in the meantime EIHA has decided to carry out extensive toxicology studies on CBD and THC conducted by a third party²⁵.

Judgement of the hemp industry in the food sector

In Lachenmeier *et al.*’s conclusion, the authors quote that “Currently CBD users must be aware that they may be ‘participating in one of the largest uncontrolled clinical trials in history’”. EIHA does not accept such an insinuation.

The quote ‘participating in one of the largest uncontrolled clinical trials in history’ is from a Newsweek article calling for attention to a new supposed scandal (see ref 33²⁶ in Lachenmeier *et al.*), and is stated by Pal Pacher, an investigator at the National Institutes of Health in the US. It should be noted that this is his own personal opinion and also refers to the situation in the US and not in Europe. In the US, there are different regulations and THC limits for products. It is not known at all to which products with which THC-contents Mr Pacher refers to in his statement. However, since Lachenmeier *et al.* use this quote in their publication, they are effectively transferring this statement to the whole European hemp industry without any critical review to the situation in Germany and Europe. This statement

is not supported by any evidence of accordingly serious incidents or poisoning, which can be attributed to the intake of these so-called “unsafe” products (see the UK FSA statement cited (footnote 4)) in Germany or the EU. So, where is the evidence for the purported side effects and products being unsafe?

Notably, EIHA’s members and other professional market operators would like to iterate that they do not use their customers as human guinea pigs.

Proposal for a legal ban on hemp extracts

Finally, the authors of the publication suggest that “*products based on hemp extract with a similar composition could be treated as illegal narcotics, prescription drugs or novel foods in order to resolve conflicting rules in the field of narcotics, drugs and food law*”. We feel that this statement is unsubstantiated.

It is well known that the legal classification of the products offered on the market depends on the composition of the products, on the way they are processed and, above all and primarily, on their objective intended use! Of course, products containing cannabinoids can – depending on their objective intended use – be used for food, food supplements, cosmetic products or as pharmaceuticals as well. It is known and common knowledge that certain food ingredients and substances may be legally sold both as food supplements and as pharmaceuticals, as their use and declaration depends mainly on the dosage of the active ingredient(s) and the method of administration, e.g. the route of administration (oral or intravenous or other) and of course depends on the intended and declared use.

One of many examples is melatonin, where the low-dose substance is sold as a food supplement and the higher-dose form can be sold as a medicinal product (this is the case in Germany at least). Another example is garlic, which is sold as a food, food supplement and pharmaceutical, depending on its use and dosage form. In this case, the ECJ only a few years ago decided exactly on this juxtaposition of food (food supplement) and medicines. Since the authors of the publication work in this field²⁷, we feel that this should be well known.

It is also common knowledge that lawful use depends on the definitions and legal provisions of the legislation enacted by the EU (in particular (EC) 178/2002 on the general principles of food law, and, for its delimitation, Directive 2001/83/EC²⁸ on medicinal products for human use) and the case law of the ECJ which completes and complements them. In addition, we have the Directive on Food Supplements 2002/46/EC in the

²⁴ Examples of such companies are known to the EIHA and discussed with the corresponding author.

²⁵ <https://eiha.org/2020/06/16/novel-food-pioneering-scientific-studies-commissioned-by-eiha/>

<https://canna-biz.legal/author/cannabizlegal/>

<https://hempindustrydaily.com/european-hemp-group-members-approve-plan-for-cbd-thc-studies/>

²⁶ <https://www.newsweek.com/2019/09/06/cbd-oil-miracle-drug-science-1456629.html>

²⁷ Lachenmeier, Walch: Cannabidiol (CBD): a strong plea for mandatory pre-marketing approval of food supplements, Journal of Consumer Protection and Food Safety,

<https://doi.org/10.1007/s00003-020-01281-2>

²⁸ https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf

EU, which explicitly permits food supplements with “nutritional as well as physiological effects”. Most CBD products on the EU market fall into this category and are therefore not allowed to have a “pharmacological, immunological or metabolic action” (medicinal products by function pursuant to Medicinal Products Directive), and they are not allowed to claim any diagnostic, curative or therapeutic effect or to present themselves as such (the latter as so-called “medicinal products by presentation”).

However, it is also undeniable that natural CBD in food or food supplements is useful and justified because of its physiological effects (in low doses far from those used medicinally)²⁹ – just like other natural substances – especially in the natural matrix of a hemp extract. Even the World Health Organization reports this in its comprehensive latest study from 2018 on Cannabis and THC³⁰.

Therefore, it is not clear why the above-mentioned legal principles and those developed by case law on their classification as food/ingredient should not apply to products containing hemp. The opinion and demand made by Lachenmeier *et al.* in their conclusions would ultimately mean a general ban on the

current use and marketing of products containing hemp as food ingredients. But there is no plausible reason for this, and certainly no scientifically recognised reason.

Summary

We conclude that the content of the publication by Lachenmeier *et al.* has fundamental flaws, and, in our opinion, does not meet the expectations of a scientific work that should be based on clear facts and evidence. Accordingly, we would suggest that due to its scientific shortcomings, as outlined above, it cannot be consulted and used without restriction for the objective and correct assessment of concrete facts.

Nevertheless, EIHA would like to confirm that unfortunately there are certainly a few products on the market that do not contain the level of cannabinoids stated on the label, or which make unjustified and unauthorised health claims on physiological effects. EIHA therefore supports the creation of clear industry standards that are mandatory for all food operators in this segment to ensure legal compliance and safety for both producers and consumers. By now many FBO's already submit themselves to a “self-regulated” quality standard, which is why we are currently trying to harmonise these standards as to scope and values – there are already some proposals on the table and work is in progress.

EIHA is working meticulously with the EU Commission and other industry groups on the concepts of a reliable quality assurance system for industrial hemp products. The corresponding proposals will be presented soon, after which they will be assessed by an EU legislator.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

²⁹ See e.g. Australian Government, Department of Health, Therapeutic Goods Administration: Safety of low dose cannabidiol, Version 1.0, April 2020.

<https://www.tga.gov.au/alert/review-safety-low-dose-cannabidiol>.

S. Shannon *et al.* :Cannabidiol in Anxiety and Sleep: A Large Case Series, The Permanente Journal 2019;23:18-041, <https://doi.org/10.7812/TPP/18-041>

³⁰ WHO Expert Committee on Drug Dependence, Fortieth Meeting, 4–7 June 2018: Cannabidiol (CBD), Critical Review Report: <https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf>

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 24 August 2020

<https://doi.org/10.5256/f1000research.27978.r68709>

© 2020 Grassi G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gianpaolo Grassi

Research Centre for Industrial Crops, Council for Agricultural Research and Economics (CREA-CIN),
Rovigo, Italy

09/09/2020: Editorial Note

Since the publication of the peer review report, it has been brought to the editorial team's attention that some Competing Interests had not been declared. As part of F1000Research's editorial policies, reviewers are required to declare any competing interests, including financial competing interests, which may influence their peer review report. We have since confirmed with Dr Grassi that they have the following competing interests, which have been added to their peer review report:

Gianpaolo Grassi has the following competing interests:

- 1) He contributed to the EIHA sponsored guidelines for THC.
- 2) He collaborated with Valoya, which led to the development of Canna+ line products.
- 3) He was an invited speaker at an EIHA conference in 2015.

For the above competing interests he has never received money directly, but Valoya has supported projects in the public research institute where he was in charge. EIHA has never paid any consultant fee or contributed in any way to his research activities.

He has been retired since last April and confirms these competing interests have not affected his ability to write an objective and unbiased review of the article.

One of the most abundant problems in the article by Lachenmeier *et al.* (2020) is confusion. Many of these topics involved are described by previous reviewers and very well by Kruse and Beitzke. I would like to point out the problem of the heterogeneity of the products sampled and tested. They are very different from each other and certainly produced by many companies, in very different

conditions, using variable botanical raw materials, of European and non-European origin. The origin adds great confusion to the discussion because if we consider the European hemp varieties we should find in them no more than 0.2% THC and therefore its residues in oil and extracts should be affected by this condition. In non-European varieties we have often found the THC level over 1% (five times the European level) and obviously the THC contamination of oils and extracts will be higher than in products derived from European varieties. Raw materials derived from non-European varieties are widely used in Italy because they are cheaper than European or Italian hemp raw materials (seeds and dried leaves).

In Italy, the Ministry of Health has received in previous years only two reports of side effects derived from hemp oil, without the addition of CBD. The reason was that the origin of the seed used to extract the oil was from China and was used as a supplement taken over a long period of time with high daily doses prescribed by the doctor to a child and a young woman.

A large number of samples tested by Lachenmeier *et al.* (No. 12) are leaves and flowers used as tea. In this situation the natural cannabinoid content cannot be modified by purification so only the harvest time and the age of the leaves could have a relationship with the THC content which will always be present, but certainly less than 0.2%. Tea preparation involves a high temperature for extraction and this always causes the complete decarboxylation of THC and the activation of its psychotropic effect.

When we consider the samples evaluated by Lachenmeier *et al.* in the article, they mostly derive from CBD extract which we could find obtained in two main ways: 1. Concentrated cannabinoids (full spectrum) and 2. Purified CBD (99% pure in crystalline form).

The most trusted companies use pure CBD derived from crystals dissolved in vegetable oils (sesame, olive, sunflower or hemp seeds). In the case of hemp seed oil, THC contamination is certainly in the 1-5 ppm range and this concentration is admitted by many European countries (Germany, Italy). CBD supplement or foods derived from crystallized non-psychotropic cannabinoids (CBD and CBG) should be identified on the product label so that consumers can be properly informed and could identify a company that describes it correctly the origin of the Product.

Many of the problems related to the "THC-like" side effect could be avoided if the origin of the product or standardization of production could include the block chain procedure or a consortium of manufacturers following a strict production protocol (e.g. see Canadian Manufacturers Test Pledge). It is a consequence of the lack of complete and clear rules and control by third parties (National Authority) because the hemp and cannabis market includes hundreds of products with many origins and the safety of the active ingredients must be guaranteed.

The suggestions to the Authorities listed in Kruse and Beitzke's document have been underlined in many countries for years and years, but politics has little interest in regulating the laws and the cannabis market probably because the size of this market is too small or probably because it is interesting for some lobbies.

However, in the paper by Lachenmeier *et al.* there is a lot of confusion and opinions that are outside the scientific task of such a publication. Confusion is very often the strategy used to limit the ability of consumers and public opinion to make their own choices. In extreme situations, lies

add to the confusion and in the case of cannabis this has been done frequently. It should be time for Europe to consider the topic of cannabis correctly and could make an objective choice supported by scientific evidence where opinion or personal orientation as reported in the article by Lachenmeier *et al.* should be omitted.

Is the rationale for commenting on the previous publication clearly described?

Yes

Are any opinions stated well-argued, clear and cogent?

Yes

Are arguments sufficiently supported by evidence from the published literature or by new data and results?

Yes

Is the conclusion balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: Gianpaolo Grassi has the following competing interests: 1) He contributed to the EIHA sponsored guidelines for THC. 2) He collaborated with Valoya, which led to the development of Canna+ line products. 3) He was an invited speaker at an EIHA conference in 2015. For the above competing interests he has never received money directly, but Valoya has supported projects in the public research institute where he was in charge. EIHA has never paid any consultant fee or contributed in any way to his research activities. He has been retired since last April and confirms these competing interests have not affected his ability to write an objective and unbiased review of the article.

Reviewer Expertise: Plant breeding, hemp, cannabis, cannabinoids, foods, regulation, THC

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reader Comment 05 Sep 2020

Dirk W. Lachenmeier, Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, Germany

As the reviewer is mostly concerned about our original article¹, we hereby want to shortly comment about the following points:

- Confusion about CBD products on the market

A major point of Dr. Grassi appears to be the “confusion” about the commercial market with CBD products, meaning a large heterogeneity of the products sampled and tested in our article¹. We actually agree with this assessment, which is also in line with Kruse and Beitzke², when they speak about “free riders”, “black sheep” or “cowboys” contributing to a substantial part of the market. What we cannot agree with is why it might not be appropriate to describe this “confusing” CBD market, which is just a reality. It should be

considered that all the samples described in our article¹ were submitted by the responsible food control authorities for evaluation, and the sampling comprised all sectors of the market including internet retailers. Would it not even be in favour of the reputable part of the hemp industry if food control removes the illegal segment of the market, such as the ones using cheaper imported material with unacceptable levels of contamination?

- Reports of side effects of CBD products

We thank Dr. Grassi for sharing the reports about side effects of hempseed oil from China. In v3 of our article¹, we have considerably expanded the section about side effects due to the many recent publications about this topic (see also our detailed response³). An additional article was published more recently summarizing poison control center cases (US national data)⁴. From the total number of cases involving cannabis and synthetic cannabinoids, cannabidiol cases increased from 0% in 2009-2018 to 17% of all cases in 2019⁴. As of August 31, 2020, poison control centers have managed 1,300 cases in 2020 related to cannabidiol⁵.

- Inclusion criteria for samples

The reviewer is correct that we included all products advertised as “CBD” in our sample. This naturally includes some teas, which are sold with designations such as “CBD flowers”. Regarding risk assessment, it must be considered that we have not even included THC formation from decarboxylation during tea preparation (the samples were analysed without heating). Finally, none of the samples on the German market were based on purified CBD (99% pure in crystalline form) or synthetic CBD but all were “full spectrum hemp extracts”.

- Tolerated THC levels in Germany

The reviewer is incorrect in stating that Germany admits THC contamination in the 1-5 ppm range. As stated in our article¹, the German guidance value for foods in general including food supplements is 150 µg total THC/kg (=0.15 ppm).

- Future strategy for a regulated CBD market

First and foremost, we want to refuse the allegations that our article¹ is reporting lies, confusion and opinions. Our research might not represent a favourable picture of the current state of the European CBD industry; however, this finding clearly does not invalidate our scientific results, which were in the meantime replicated by other authorities⁶⁻⁷. Nevertheless, we actually agree with Dr. Grassi that we need a regulation of the CBD market along with clear-cut criteria for enforcement. We actually have formulated such a policy need for years and also have similarly concluded in our article¹. We also agree with strict rules about labelling (such as identity and property of the used CBD extract) as well as process control on all steps and traceability. Basically, most of these demands are already mandatorily included in European food laws, and the lack of implementing them is another example of the non-compliance of a part of CBD industry.

References

1 Lachenmeier DW, Habel S, Fischer B et al. Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 3; peer review: 2 approved, 1 approved with reservations]. F1000Research 2020, 8:1394 (<https://doi.org/10.12688/f1000research.19931.3>)

2 Kruse D and Beitzke B. Comment on Lachenmeier et al (2020) “Are side effects of

cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?":
disputation on various points in the publication [version 1; peer review: 1 approved].
F1000Research 2020, 9:900 (<https://doi.org/10.12688/f1000research.25354.1>)

3 Lachenmeier DW and Walch SG. Evidence for side effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association [version 1; peer review: awaiting peer review]. F1000Research 2020, 9:1051 (<https://doi.org/10.12688/f1000research.26045.1>)

4 Choi NG, Marti CN, DiNitto DM, Baker SD. Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009–2019. Clinical Toxicology 2020, in press (<https://doi.org/10.1080/15563650.2020.1806296>)

5 National Poison Data System. Track Emerging Hazards. Cannabidiol (CBD) National Poison Data System, American Association of Poison Control Centers. 2020. [Reference Source](#)

6 FSAI: Consumers being put at risk and misled with some CBD food supplements. Food Safety Authority of Ireland; 2020. [Reference Source](#)

7 European Commission: Rapid Alert System for Food and Feed (RASFF). Brussels, Belgium. European Commission; 2020. [Reference Source](#)

Competing Interests: No competing interests were disclosed.

Reviewer Report 10 August 2020

<https://doi.org/10.5256/f1000research.27978.r68710>

© 2020 Nahler G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gerhard Nahler

CIS Clinical Investigation Support GmbH, Vienna, Austria

21/08/2020: Editorial Note

Since the publication of the peer review report, it has been brought to the editorial team's attention that some Competing Interests had not been declared. As part of F1000Research's editorial policies, reviewers are required to declare any competing interests, including financial competing interests, which may influence their peer review report. We have since confirmed with Dr Nahler that they have the following competing interests, which have been added to their peer review report:

Gerhard Nahler works as independent consultant. Among others, he is consultant of the non-profit NGO

"ICANNA", the EIHA and a number of pharmaceutical industries.

In order to understand the counterstatement of Kruse and Beitzke (2020) it is necessary to read the article of Lachenmeier *et al.* (2020¹) first.

1) The primary message of Kruse and Beitzke in their Abstract is that no proof for putative side effects/adverse effects caused by "CBD-products" is provided by Lachenmeier *et al.* (2020), nor that such side effects are caused by THC.

2) The second point is a lack of clarity about the term "THC" used by Lachenmeier *et al.* Is it used exclusively for the psychotomimetic delta-9-tetrahydrocannabinol (?), the non-psychotomimetic delta-9-tetrahydrocannabinolic acid (?), for a mixture of both substances such as occurring in hemp tea (?), or also for an analogue, delta-8-tetrahydrocannabinol (?) which is a minor byproduct with lower psychotomimetic properties in hemp extracts?

3) The third point concerns the "safety" of commercial CBD-products analysed by Lachenmeier *et al.*, in relation to the content of THC. Here, Kruse and Beitzke criticise unrealistic assumptions concerning the calculation of the supposed daily intake of CBD-products and a lack of clarity of the table 2 in the main part of Lachenmeier's article (concentrations of cannabinoids are communicated by Lachenmeier *et al.* only as a separate supplemental material; without, the reader cannot verify the assumptions of Lachenmeier *et al.*).

Ad 1) According to the title, the article of Lachenmeier *et al.* (2020) focuses on "**side effects of cannabidiol (CBD) products**" caused by "**contamination**" with THC. As CBD products vary widely in their composition beyond CBD as main ingredient, a more detailed characterisation of products, their composition and various other phytochemicals, as well as a comparison to the characteristic side effects of the two pure substances, CBD and delta9-tetrahydrocannabinol (in short THC) would help to better understand the differences. In Lachenmeier's article, various CBD-products based on hemp extracts or flowers, often consumed as "supplements", are addressed, therefore containing not only CBD but a number of other phytosubstances, such as delta9-tetrahydrocannabinol (in short THC) among numerous other natural byproducts in varying ratios. The nature and quantities of these other byproducts depend, among many others, on the extraction process and may also include the respective acids CBDA and THCA which have different properties compared to the decarboxylated substances CBD and THC. Lachenmeier's article focuses therefore on ill characterised "CBD-products". As a uniform "CBD-product" does not exist, products likely vary in their activity and side effect profile. The statement of Lachenmeier *et al.* on page 6 "*our results provide compelling evidence that THC natively contained in CBD products by contamination may be a direct cause for side effects of these products*" is not supported by a listing of such side effects, including their frequencies and/or the respective literature. The title of Lachenmeier's article assumes that side effects occur with CBD-products and the reader might expect that this will be further addressed in the article; however, this is not the case. The only "side effects" reported read as follows (section "Introduction"): "*some pediatric studies in epilepsy patients with orally administered CBD also reported adverse effects such as drowsiness and fatigue that could be explained by pharmacological properties of THC rather than of CBD (8–10).*" A further, more detailed description of the nature of side effects supposed to be caused by THC in CBD-(food) products is missing. This is clearly criticised by Kruse and Beitzke. Patients in the articles referenced by

Lachenmeier *et al.* received either extracts (Ref.8, a US parent-survey) or pure CBD (CBD/Epidyolex of GW, purity ~99% with $\leq 0.1\%$ THC) for treatment-resistant epilepsy and in daily dosages exceeding in some cases 25mg CBD/kg body weight. These subjects received, however, antiepileptic drugs in addition, known to cause, e.g., sedation. Therefore, this can hardly serve as reference for side effects of CBD-products (notably food-products, hemp extracts) taken by a normal, healthy population as is addressed by Kruse and Beitzke. Indisputable differences are therefore the product itself (pure CBD vs. mixtures of phytocompounds), the population (patients vs. healthy individuals) and the intake (regular, high concomitant therapeutic doses vs. low dose, often taken occasionally).

Although this would be of considerable interest, the reviewer is unaware of any systematic evaluation of side effects supposed to be related to CBD-containing, hemp-derived food products. On the contrary, CBD has been described to reduce side effects of THC as has been commented by Kruse and Beitzke. In the article cited (Zuardi *et al.*, 1982²) a mixture of CBD with THC (ratio 2:1) attenuated anxiety reactions caused by THC. In hemp, the ratio of CBD:THC is much higher, typically around 20:1; such a modified ratio may also have modified effects which can be further influenced by other phytocompounds. Pure CBD seems to be safe; after excluding studies in childhood epilepsy, the only adverse outcome associated with CBD treatment was diarrhoea (Chesney *et al.*, 2020³). In the EFSA report (EFSA, 2015⁴) the lowest observed adverse effect level (LOAEL) of 2.5 mg $\Delta 9$ -THC/day, corresponding to 0.036 mg $\Delta 9$ -THC/kg b.w. per day, was derived from "*observed central nervous system (CNS) effects (i.e. slight euphoric effects), as well as the increase in heart rate*" [according to a more recent review, "*a dose of 7.5 mg (THC) did not affect heart rate or blood pressure*" (WHO, 2018⁵)]. It has to be reminded that the effect of THC on the heart rate is dose-dependent and transient, and disappears after repeated administration. Whether a slight euphoric effect is "*adverse*" or not may be disputable and still depends on the situation. Drowsiness or fatigue is uncommon with very low doses of THC.

Ad 2) Although not explicitly stated, "THC" is the psychotomimetic delta-9-tetrahydrocannabinol. If the term is used for "mixtures" this may cause misunderstandings. This may have been the case when Lachenmeier *et al.* refer to hemp tea, even if it is a common analytical procedure to exhibit the sum of **THC + THCA as "THC" for forensic** reasons. In addition to request a discriminate use of the term "THC", Kruse and Beitzke address also in their counterstatement the aspect of an appropriate "labelling" and of mandatory "industry standards" for CBD-products in order to limit a negative impact by "black sheeps" on the reputation of the whole hemp industry. This is highly welcome in the interest of the scientific community, and would be a considerable step forward as it makes discreditation of CBD-products and of the hemp industry less likely; this is clearly encouraged by Kruse and Beitzke. Although not explicitly mentioned as such by Kruse and Beitzke, it is obvious that a correct declaration of the content should not be restricted to the recommended daily consumption and the amount of CBD.

Ad 3) In table 2 of Lachenmeier's article, all samples for which "*THC > LOAEL*" are marked in red (17 out of 40 samples); of these 17, seven samples*) (41%) are "hemp teas". As this is a notable percentage it deserved a closer look by Kruse and Beitzke. The calculation of the THC-exposure after consumption of tea made from hemp flowers and/or leaves by Lachenmeier *et al.* is misleading: First, cannabinoids are almost water-insoluble, therefore an extraction of the total amount of THC contained in 8g of dry herbal substance by hot water – as has been assumed in Lachenmeier's article – is impossible. Even when drug-type cannabis was used for preparation of a tea, the concentration after 20 minutes of boiling (which is not common practice for preparing tea)

was 0,043 mg THCA/mL und 0,01mg THC/mL (Hazekamp *et al.*, 2007⁶) or 1.0 to 2.4mg THC per liter according to others (Giroud *et al.*, 1997⁷, cited by Hazekamp *et al.*, 2007). Consumption of two cups of tea, prepared as usual by pouring hot water on dry herbal substance and simmering for about 10 minutes, would normally not result in an uptake of THC exceeding the amount of the lowest observed adverse effect level (LOAEL). This is an important objection made by Kruse and Beitzke. The second, minor overestimation concerns the amount of 8g of dry herbal substance consumed per day. Regular tea bags usually weigh 1.5-2 grams; 8g correspond to 4 to 5 cups of tea per day; this seems to be a rather high consumption, above the average. (The exposure by other CBD-products than hemp tea has not been reviewed).

When Lachenmeier *et al.* use, in addition to “side effects”, the term “**unsafe**” for CBD-(food-) products, Kruse and Beitzke request, for the sake of clarity, an explanation why they are “unsafe”, i.e., a description of any, putative or confirmed, short- or long-term negative impact of CBD-products on human health. “Safe” or “unsafe” for food commonly implicates a broader impact on human health than (isolated) side effects. Food can induce, as an example, allergic reactions as side effects still being safe for the large majority of consumers.

In short, Kruse and Beitzke clearly describe a number of points in Lachenmeier’s article which would deserve clarification.

*)

190267605

180630663

190595270-tea

180776480

190490183-tea

190595273-tea

190595267-tea

190203194

180598182

190495001-tea

190203193

180781746

190400870-tea

180198245

180198246

180598187

190176314-tea

(7 of 17 samples); in table 2 of Lachenmeier’s article all samples for which „THC > LOAEL“ are marked in red (17 out of 40 samples); of these 17, seven samples (41%) are “hemp teas”.

References

1. Lachenmeier DW, Habel S, Fischer B, Herbi F, et al.: Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?. *F1000Res.* 2019; **8**: 1394 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG: Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. *Psychopharmacology (Berl).* 1982; **76** (3): 245-50

[PubMed Abstract](#) | [Publisher Full Text](#)

3. Chesney E, Oliver D, Green A, Sovi S, et al.: Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. *Neuropsychopharmacology*. 2020. [PubMed Abstract](#) | [Publisher Full Text](#)

4. EFSA Panel on Contaminants in the Food Chain CONTAM: Scientific Opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. *EFSA Journal*. 2015; **13** (6). [Publisher Full Text](#)

5. WHO 2018 Expert Committee on Drug Dependence Pre-Review: Delta-9-tetrahydrocannabinol. Section 3: Toxicology. *World Health Organization*. 2018. [Reference Source](#)

6. Hazekamp A, Bastola K, Rashidi H, Bender J, et al.: Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. *J Ethnopharmacol*. 2007; **113** (1): 85-90 [PubMed Abstract](#) | [Publisher Full Text](#)

7. Giroud C, Augsburg M, Rivier L, Mangin P: Hemp tea versus hemp milk: subjective effects and elimination studies of THC and its main metabolite. *Proceedings of the 35th TIAFT meeting, Padova, Italy*. 1997. 112-121

Is the rationale for commenting on the previous publication clearly described?

Yes

Are any opinions stated well-argued, clear and cogent?

Yes

Are arguments sufficiently supported by evidence from the published literature or by new data and results?

Yes

Is the conclusion balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: Gerhard Nahler works as independent consultant. Among others, he is consultant of the non-profit NGO "ICANNA", the EIHA and a number of pharmaceutical industries.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reader Comment 05 Sep 2020

Dirk W. Lachenmeier, Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, Germany

We thank Dr. Nahler for his comments, which mostly refer to our original article¹. For this reason, we want to clarify some further points:

Ad 1) The evidence regarding side effects was considerably increased since the initial publication of our article, and several studies were added in v3¹, see also our detailed response² and our comment to reviewer #2 (Gianpaolo Grassi) above.

Ad 2) The issue of EIHA about the definition of THC has also been clarified in v3¹. We did not use the term for any “mixture” but only for the psychoactive Δ^9 -tetrahydrocannabinol. However, we wonder about the comment regarding mandatory “industry standards”. How can an industry standard be made mandatory, so that it might resolve the problem of “black sheeps”? They would just similarly ignore the industry standard as they currently ignore the laws and regulations, including those for novel food approval as well as for labelling of food supplements.

Ad 3) The questions regarding exposure assessment are answered in our detailed response article². The question of Dr. Nahler regarding the term “unsafe food” can be answered by looking at the basic food regulation of the European Union:

Article 14 of Regulation (EC) No 178/2002³ sets out food safety requirements. It requires that food must not be placed on the market if it is unsafe. Food shall be deemed to be unsafe if it is considered to be: i) injurious to health or ii) unfit for human consumption. A criterion commonly applied to determine if a food is deemed unsafe is exceedance of the acute reference dose (ARfD) (see, e.g., Refs. 4-5). A well-founded evaluation of the safety of substances such as THC in foods thus combines exposure calculations based on consumption data and toxicological studies such as the ones found in the scientific opinions of the European Food Safety Authority (EFSA). Our evaluation on a case-by-case basis for each sample based on the EFSA assessment of THC⁶ showed that typical intake scenarios would lead not only to the exceedance of the ARfD but also to the exceedance of the Lowest Observed Adverse Effect Level (LOAEL) of 2.5 mg/day, which is clearly to be judged as “injurious to health” according to the criteria of Regulation (EC) No 178/2002³. It must be mentioned that there appears to be less controversy about lowest observed effect levels of THC than regarding the uncertainty factors to derive ARfD values or acceptable daily intake values (e.g. compare the EFSA position⁶ to the industry position⁷).

References

1 Lachenmeier DW, Habel S, Fischer B et al. Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 3; peer review: 2 approved, 1 approved with reservations]. F1000Research 2020, 8:1394 (<https://doi.org/10.12688/f1000research.19931.3>)

2 Lachenmeier DW and Walch SG. Evidence for side effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association [version 1; peer review: awaiting peer review]. F1000Research 2020, 9:1051 (<https://doi.org/10.12688/f1000research.26045.1>)

3 European Parliament and Council: Regulation (EC) No 178/2002 of the European Parliament and of the council of 28 January 2002 laying down the general principles and requirements of food law establishing the European Food Safety Authority and laying down procedures in matters of food safety. *Off J Europ Comm.* 2002; **L31**: 1–24. [Reference Source](#)

4 Polinski D, van der Meulen BMJ. Unfit for human consumption. The elusive element in the EU food safety concept of article 14 GFL (April 13, 2019). European Institute for Food Law Working Paper Series 2019/01. Wageningen, The Netherlands (<http://dx.doi.org/10.2139/ssrn.3371444>)

5 Meisterernst A. Gesundheitsschädliche Lebensmittel. In: Lebensmittelrecht. 2020. Verlag C.H. Beck, Munich, Germany (<https://doi.org/10.17104/9783406759703-15>)

6 EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. *EFSA J.* 2015; **13**(6): 4141. [Publisher Full Text](#)

7 Sarmiento L, Carus M, Grotenhermen F, Kruse D, Nahler G, Pirich E, Brenneisen R, Grassi G. Scientifically Sound Guidelines for THC in Food in Europe. 2015. Nova-Institute, Hürth, Germany (<https://pdfs.semanticscholar.org/117b/267905764ec7cc8bb64a0aa717959130c2df.pdf>)

Competing Interests: No competing interests were disclosed.

Comments on this article

Version 1

Reader Comment 05 Sep 2020

Dirk W. Lachenmeier, Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, Germany

As promised in our previous comment, the scientific points have now been answered in a correspondence article with a detailed rebuttal of all points raised¹.

References:

1 Lachenmeier DW and Walch SG. Evidence for side effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association [version 1; peer review: awaiting peer review]. *F1000Research* 2020, 9:1051 (<https://doi.org/10.12688/f1000research.26045.1>)

Competing Interests: No competing interests were disclosed.

Reader Comment 10 Aug 2020

Dirk W. Lachenmeier, Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, Germany

We thank Kruse & Beitzke on behalf of the European Industrial Hemp Association (EIHA) for their detailed comment¹ on our previous article² regarding the risk assessment of cannabidiol products. The scientific points will be answered in a separate correspondence article with a detailed rebuttal

of all points raised. In short, we disagree with the arguments of the EIHA¹ and believe our article² is scientifically valid as our detailed response will show.

Regarding the current correspondence article of Kruse & Beitzke¹, we have the following remarks that might be considered in the next revision of the article:

1. Introduction, third dash point: Our article² is misquoted. The correct quotation must read "placed unsafe and **un**approved products on the market".
2. "THC definition": As already detailed in response to the third review of our article², we exclusively report the specific content of psychotropic Δ^9 -THC but not "total THC". Hence, this point could be dropped as it has been adequately resolved due to the peer review and has been clarified in v3 of our article³.
3. Tea products, footnote 10 mentioning data about hemp leave infusions: According to the data availability policy of F1000 Research, it would be valuable to include the source data allowing others to analyse the data and corroborate the claims about the data.
4. Cannabis shot: There appears to be a misunderstanding about what is a "shot". A shot is a form of concentrated beverage and not a food supplement. The whole portion of the "shot" is intended by the manufacturer to be consumed at once (e.g. compare "shots" of energy drinks). The "shot" point could therefore be dropped as there should be no discussion around the consumption amount.
5. Proposal for a legal ban on hemp extracts, first paragraph: Our article² is again misquoted. The correct quotation must read: "For cannabis-derived products, such as CBD, the problem is aggravated by conflicting regulations in the narcotic, medicinal, and food law areas. For example, hemp extract-based products of similar composition could be treated as illegal narcotics, prescription-based medicinal products, or novel foods." The validity and relevance of this remark is currently confirmed by the recent suggestions to regulate CBD products on European Union (EU) level as narcotics (see #10 below).
6. Sections "Alleged illegality of all hemp products containing CBD" and "Value judgement on food producers of hemp products": Both paragraphs separately and disconnectedly try to present evidence about interpretation of the novel food regulation. It would be preferable if this information would be presented in a logical fashion at a single instance, i.e. in the first section as it basically has nothing to do with "value judgements on food producers" but refers to the legality of the products. More preferably, the claimed evidence about consumption of hemp extracts as food before 1997 should be included as source data allowing others to analyse the data and corroborate the claims about the data.
7. Section "Alleged illegality of all hemp products containing CBD": the second part of the section is regarding another topic, namely the suggestions of self-regulating the industry. It would be more concise if this argument is expanded at the end of the article combined with the information in the summary section.
8. Proposal for a legal ban on hemp extracts: the title of the section is misleading as the authors do not propose a legal ban but just discuss the potential legal fields into which hemp extracts could fall and the difficulties in legal demarcation. At the end of the article a regulated legalization is suggested and not a ban.
9. Summary: Can this section be called "conclusion"? It does not summarize the text but goes beyond and proposes some concepts to regulate the industry.
10. Summary: at the end of the summary it would be worthwhile to expand the information about the meticulous working of EIHA with the EU commission. It is hard to imagine that the

commission is meticulously working with a single industry lobbyist in shaping regulations of cannabis. Contrarily according to recent press information⁴, the EU commission currently considers to define hemp extract-based products as narcotics, and hence as non-foods. For this reason, the cannabidiol novel food applications were not validated but sent back to the applicants for comments⁴.

11. References: The references do not completely conform to the authors' guidelines: "Only articles, books and book chapters, datasets and abstracts that have been published or are in press, or are available through public e-print/preprint servers/data repositories, may be cited. Web links, URLs, and links to the authors' own websites should be included as hyperlinks within the main body of the article, and not as references." In deviation to this, the EIHA presents unpublished, not publicly available items as references: Ref. 10 (test reports), Ref. 12 (claims about Austria), Ref. 22a (letters from EU commission), Ref. 22b (link to authors' own website), Ref. 22c (presentation by M. Reinders), Ref. 24 (examples of such companies), Ref. 25 (link to authors' own website). Many web links are also presented as references.

References:

1 Kruse D and Beitzke B. Comment on Lachenmeier et al (2020) "Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?": disputation on various points in the publication [version 1; peer review: 1 approved]. F1000Research 2020, 9:900 (<https://doi.org/10.12688/f1000research.25354.1>)

2 Lachenmeier DW, Habel S, Fischer B et al. Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 2; peer review: 2 approved, 1 approved with reservations]. F1000Research 2020, 8:1394 (<https://doi.org/10.12688/f1000research.19931.2>)

3 Lachenmeier DW, Habel S, Fischer B et al. Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 3; peer review: 2 approved, 1 approved with reservations]. F1000Research 2020, 8:1394 (<https://doi.org/10.12688/f1000research.19931.3>)

4 Gallen T. EU CBD market under threat with narcotic classification favored. HBW Insight, Informa Pharma Intelligence. 22.07.2020. (<https://hbw.pharmaintelligence.informa.com/RS150264/EU-CBD-Market-Under-Threat-With-Narcotic-Classification-Favored>)

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research